vicodin online
News Events Profiles Clinical Management Directory

Archive for December, 2008

Cardiovascular Medicine & Thoracic Surgery Associates Declare Intent to Join WellStar

Monday, December 8th, 2008

Cardiovascular Medicine, P.C. (CVM) and Thoracic Surgery Associates. P.C. (TSA) announced in late November that they have signed letters of intent to join WellStar Health System.  This includes all five CVM locations and TSA’s Marietta location.

“Integration between our physicians and hospitals is essential for future growth,” said Gregory L. Simone, M.D., president and CEO of WellStar Health System.  “Having CVM and TSA as a part of our WellStar team, will only strengthen our high-quality cardiac and thoracic service lines and will enable WellStar to enhance its patient care.  It is a win-win for WellStar, CVM, TSA and our community.”

CVM and TSA’s approximately 210 employees, physicians and advanced practitioners will become WellStar employees. It will be business as usual for CVM and TSA patients at the existing locations.

Founded in 1980, Cardiovascular Medicine, P.C. (CVM) is the largest and most comprehensive cardiology practice in the WellStar market area with 25 physicians, 23 mid-level providers and five office locations.  CVM has been recognized annually by the Medical Group Management Association as a “Better Performer” as compared with similar group practices nationwide. The practice has achieved this distinction based on the comprehensiveness of its service offerings, proven expertise in preventive care, cutting-edge treatment of acute and chronic cardiac conditions and dedication to improving the quality of life for its patients.  CVM is accredited for their Nuclear Cardiology and Echocardiography Departments from (ICANL) and (ICAEL) respectively.

Thoracic Surgery Associates, P.C. (TSA) offers the surgical treatment of benign and malignant diseases of the lung, pleura, chest wall, mediastinum, pericardium and esophagus, as well as surgical treatment of hyperhydrosis and reflex sympathetic dystrophy of the upper extremities.  The majority of surgery performed by TSA utilizes minimally invasive techniques known as VATS (Video Assisted Thoracic Surgery) or thoracoscopy.


Greater Atlanta Medical Management Association

Friday, December 5th, 2008

December 5, 2008 –  Holiday Party


Greater Atlanta Medical Management Association – Holiday Party

Friday, December 5th, 2008

December 5, 2008 at the DeKalb Medical Center –


Lisa Borders Joins Grady’s Leadership Team

Thursday, December 4th, 2008

Lisa Borders, president of the Atlanta City Council, has been named president of thelisa-borders.thumbnail.jpg Henry W. Grady Health System Foundation. As president, Borders will lead the Foundation’s development and community outreach efforts and provide support for the Greater Grady Campaign, a large-scale capital fund-raising effort for the health system that will kick off in January 2009.

Borders has served as president of Atlanta’s city council since 2004.  Prior to joining the Foundation, Borders was CEO of LMB Group LLC, a community investment, external affairs, marketing and communications company.  She has previously worked as a senior vice president of Marketing and External Affairs with Cousins Properties, an Atlanta-based real estate investment trust.

Prior to joining Cousins, Borders worked in the health-care arena for more than 15 years.  She served as the chief administrator for Atlanta Women’s Specialists and also served as vice president of operations for Healthcap Atlanta, a physician practice management company.

Borders’ work in the community has focused primarily on family issues in the areas of education, health care and housing.  She serves as a trustee at the Westminster Schools, a board member at Clark Atlanta University, and as an advisory board member of Cool Girls and Year Up.  She is a member of Leadership Georgia and recruits and interviews students for her alma mater, Duke University.

Borders holds a bachelor’s degree from Duke University and a masters of science in health administration from the University of Colorado.


GeoVax’s Phase 2a HIV/AIDS Vaccine Human Trials Beginning in North/South America

Thursday, December 4th, 2008

GeoVax Labs, Inc., an Atlanta-based biotechnology company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced recently that the launch of its Phase 2a Human Vaccine Trials will take place in twelve sites across North and South America. These trials are conducted in collaboration with The National Institutes of Health (NIH), and the HIV Vaccine Trials Network (HVTN).

Dr. Harriet Robinson, Vice President of Research and Development of GeoVax Labs, Inc., stated, “We feel privileged to be in the position to launch our Phase 2a human trial. Going forward, each clinical site’s review board will start the vaccination process, when deemed appropriate and ready. Accordingly, HVTN’s pharmacy will release the vaccines to each designated institution as directed by each site’s local review board.”

Trial site arrangements and other details of the study were confirmed in a recent meeting held in Seattle, Washington, between the HVTN and GeoVax’s scientific personnel. The Phase 2a human clinical trial will involve 150 vaccinees and 75 placebo (control) participants. The vaccine regimen employs a two-component “prime-boost strategy.” Trial participants will first be administered a GeoVax HIV-1 DNA vaccine which “primes” the immune system followed by the second vaccine, GeoVax’s HIV-1 MVA (Modified Vaccinia Virus) boost. Both vaccines express the three major proteins of the AIDS virus. These proteins mimic more than 50% of the components of the AIDS virus (HIV-1) but cannot cause AIDS. GeoVax AIDS vaccines are designed to prevent HIV-1 virus infection which causes Acquired Immunodeficiency Disease (AIDS).

GeoVax’s core AIDS vaccine technologies were developed through a collaboration of colleagues at Emory University’s Vaccine Center, the National Institutes of Health (NIH), The Centers for Disease Control and Prevention (CDC) and the GeoVax team.



Resources F T L Subscription Advertising About Us Past Issues Contact